Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754767 · ClinicalTrials.gov registry record · Phase 4
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
A Phase 4 study, sponsored by HealthPartners Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00754767: Clinical Trial Phase 4 study, sponsored by HealthPartners Institute.
NCT00754767 is a Phase 4 study that was terminated before completion, run by HealthPartners Institute. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00754767, a Phase 4 study, was terminated before completion, sponsored by HealthPartners Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by chemotherapy in women with metastatic breast cancer.
Primary Outcome
Data was not analyzed due to study termination
Interventions
- OTHER placebo
- DRUG L-carnitine L-tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-01-02 |
| Est. Completion | 2008-05-02 |
| Phase | Phase 4 |
Why NCT00754767 stopped before completion
NCT00754767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00754767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00754767 about?
NCT00754767 is a clinical study titled "L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer". RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by chemotherapy in women with metastatic breast cancer.
What is the current status of trial NCT00754767?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2007-01-02. Estimated completion is 2008-05-02.
What interventions are being tested in trial NCT00754767?
The interventions under investigation include: placebo (OTHER), L-carnitine L-tartrate (DRUG).
Who is sponsoring clinical trial NCT00754767?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00754767's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI